RE:Q2 results It appears that they met their Revenue target for both core and Covid businesses. It also exceeded analyst expectations.
Earnings exceeded analyst expectations.
Gross Profit margin increased.
Profit decreased with decreasing Covid business
Adjusted EBIDTA increased from $5,468 to $6,847. This is a 25% increase in the midst of declining Covid business. It is more in line with the trend line established for core busienss pre-Covid.
Vent Patient levels also increased and appears to have returned to the trend line established pre-Covid.